Evolocumab, a PCSK9 inhibitor, has been notably effective in reducing the likelihood of first cardiovascular events among patients receiving statins for atherosclerotic cardiovascular disease (ASCVD) [6,7]. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trials also evaluated evolocumab's efficacy in diminishing the total cardiovascular event burden among statin-treated individuals with stable vascular disease [8,9]. This evidence concerns the gene PCSK9 and atherosclerosis.